Molecular Imaging News
May 20, 2005
NCI Announces Exploratory Grants for Quick Trials in Imaging and Image-Guided Interventions
National Cancer Institute
Applications for exploratory grants to fund quick trials in cancer imaging and image-guided intervention at the preclinical stage of development are being solicited by the National Cancer Institute, one of the National Institutes of Health.
Applications are being sought in the following areas of research:
- Phase I or II clinical trials of novel imaging-agents to assure their safety and efficacy, so that further evaluations of the clinical potentials of these agents can proceed;
- Feasibility studies in image-guided intervention, to establish treatment parameters and early therapeutic efficacy for these methods; and/or
- Clinical feasibility or "proof-of-principle" studies or clinical trials to demonstrate potential efficacy of promising discoveries in imaging or image-guided therapy methodologies or technologies, such as, but not limited to, image acquisition devices or systems, software for image-acquisition, image processing, image-guided therapy, contrast kinetic modeling, or 3-D reconstruction and quantitative tools.
Investigators may apply for a maximum of two years of funding support using the exploratory or developmental (R21) grant mechanism to cover up to $250,000 in direct costs per year. The anticipated number of awards is three to six per year. See the Related Items box below for links to the government program announcement (PAR-05-114).
These grants will also serve as direct extensions of the Development of Clinical Imaging Drugs and Enhancers (DCIDE) program, providing a mechanism for accelerated peer review and funding to support the imaging and laboratory costs of early clinical testing.